Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Cancer treatments should benefit patients: a common-sense revolution in oncology

Nature Medicine volume 28, pages 617–620 (2022)Cite this article

Subjects

Many newly approved cancer therapeutics offer limited clinical benefits yet are still prescribed to patients. A common-sense revolution in oncology would prioritize treatments that meaningfully improve survival and quality of life.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gyawali, B. et al. ESMO Open 6, 100117 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Abola, M. V. & Prasad, V. JAMA Oncol. 2, 139–141 (2016).

    Article  PubMed  Google Scholar 

  3. Abola, M. V. & Prasad, V. Mayo Clin. Proc. 91, 1668–1670 (2016).

    Article  PubMed  Google Scholar 

  4. Del Paggio, J. C. et al. JAMA Oncol. 7, 728–734 (2021).

    Article  PubMed  Google Scholar 

  5. Sharma, S. et al. J. Natl. Compr. Canc. Netw. https://doi.org/10.6004/jnccn.2021.7016 (2020).

  6. Del Paggio, J. C. et al. Lancet Oncol. 18, 887–894 (2017).

    Article  PubMed  Google Scholar 

  7. Del Paggio, J. C. et al. Ann. Oncol. 28, 157–162 (2017).

    Article  PubMed  Google Scholar 

  8. Gyawali, B. et al. Lancet Oncol. 19, 288–290 (2018).

    Article  PubMed  Google Scholar 

  9. Gyawali, B. et al. Nat. Cancer 1, 142–145 (2020).

    Article  PubMed  Google Scholar 

  10. Raphael, M. J. et al. Nat. Rev. Clin. Oncol. 17, 271–272 (2020).

    Article  PubMed  Google Scholar 

  11. Booth, C. M. et al. Nat. Rev. Clin. Oncol. 16, 312–325 (2019).

    Article  PubMed  Google Scholar 

  12. Gyawali, B. et al. Br. Med. J. 374, n1959 (2021).

    Article  Google Scholar 

  13. Gyawali, B. et al. Am. Soc. Clin. Oncol. Educ. Book 39, 374–387 (2019).

    Article  PubMed  Google Scholar 

  14. Hoffmann, T. C. & Del Mar, C. JAMA Intern. Med. 177, 407–419 (2017).

    Article  PubMed  Google Scholar 

  15. Smith, T. J. & Hillner, B. E. N. Engl. J. Med. 364, 2060–2065 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Weeks, J. C. et al. N. Engl. J. Med. 367, 1616–1625 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hoffmann, T. C. & Del Mar, C. JAMA Intern. Med. 175, 274–286 (2015).

    Article  PubMed  Google Scholar 

  18. Fundytus, A. et al. JAMA Oncol. 7, 1757–1758 (2021).

    Article  PubMed  Google Scholar 

  19. Schnipper, L. E. et al. J. Clin. Oncol. 30, 1715–1724 (2012).

    Article  PubMed  Google Scholar 

  20. Schnipper, L. E. et al. J. Clin. Oncol. 33, 2563–2577 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cherny, N. I. et al. Ann. Oncol. 28, 2340–2366 (2017).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge E. Eisenhauer (Queen’s University, Kingston, Canada) and I. Tannock (Princess Margaret Cancer Centre, Toronto, Canada) for helpful comments on an earlier draft of the manuscript. C.M.B. is supported as the Canada Research Chair in Population Cancer Care. B.G. receives salary support from the Ontario Institute for Cancer Research funded by the government of Ontario.

Author information

Authors and Affiliations

  1. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Kingston, Canada

    Bishal Gyawali & Christopher M. Booth

  2. Department of Oncology and Department of Public Health Sciences, Queen’s University, Kingston, Canada

    Bishal Gyawali & Christopher M. Booth

Authors
  1. Bishal Gyawali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher M. Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

B.G. and C.M.B. contributed equally to the manuscript, including its conception, writing and editing.

Corresponding author

Correspondence to Bishal Gyawali.

Ethics declarations

Competing interests

B.G. has received consulting fees from Vivio Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Booth, C.M. Cancer treatments should benefit patients: a common-sense revolution in oncology. Nat Med 28, 617–620 (2022). https://doi.org/10.1038/s41591-021-01662-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01662-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing